Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Collagens in the extracellular matrix (ECM) provide a physical barrier to tumor immune infiltration, while also acting as a ligand for immune inhibitory receptors. Transforming growth factor-β (TGF-β) is a key contributor to shaping the ECM by stimulating the production and remodeling of collagens. TGF-β activation signatures and collagen-rich environments have both been associated with T cell exclusion and lack of responses to immunotherapy. Here, we describe the effect of targeting collagens that signal through the inhibitory leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) in combination with blockade of TGF-β and programmed cell death ligand 1 (PD-L1). This approach remodeled the tumor collagenous matrix, enhanced tumor infiltration and activation of CD8+ T cells, and repolarized suppressive macrophage populations, resulting in high cure rates and long-term tumor-specific protection across murine models of colon and mammary carcinoma. The results highlight the advantage of direct targeting of ECM components in combination with immune checkpoint blockade therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 13×
“Several studies have now linked a gene signature of TGF-β activation in tumors with T cell exclusion and lack of responses to ICB therapy (15–17).”
InfluentialMatrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151 · cited 1×
“Denatured or remodeled collagens can arise from the activity of matrix metalloproteinases secreted by tumor, immune, or stromal cells (42).”
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286 · cited 1×
“…of tumor biomarkers in clinical studies across various tumor types have identified factors that associate with response to ICB, including expression of PD-L1 on both tumor cells and tumor-infiltrating lymphocytes (TILs), tumor mutational burden, and TIL density, location, and activation (2).”
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 1×
“Several studies have now linked a gene signature of TGF-β activation in tumors with T cell exclusion and lack of responses to ICB therapy (15–17).”
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140 · cited 1×
“Beyond these factors, the presence of a collagen-dense extracellular matrix (ECM) and high numbers of immunosuppressive myeloid cell populations are increasingly being recognized as critical determinants of tumor responses to ICB therapy (3).”
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070 · cited 1×
“A study across all molecular subtypes of CRC has demonstrated that a gene program induced by TGF-β in tumor stromal cells can predict poor prognosis across all subtypes (44), leading to the question of whether TGF-β and TGF-β –induced collagens could play a role in CRC resistance to ICB.”
Chakravarthy, A., Khan, L., Bensler, N. P., Bose, P., & De Carvalho, D. D. (2018) · Nature Communications · doi:10.1038/s41467-018-06654-8 · Cited by 656
Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406 · cited 1×
“A clinical-stage agent (23, 30), bintrafusp alfa was shown in preclinical models to reduce TGF-β –mediated tumor EMT (31), enhance the cytolytic ability of T and NK cells, and synergize with other immunotherapies to mediate tumor control (21, 26).”
Self-citationLind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247 · cited 1×
“Immune checkpoint blockade (ICB) therapies targeting the programmed cell death 1 receptor (PD-1) or its ligand PD-L1 have shown unprecedented clinical benefit across various cancer types, yet durable responses have been achieved only in a limited subset of patients (1).”
Self-citationKnudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195 · cited 1×
“While both MC38 and EMT6 are considered inherently immunogenic, previous reports have shown that both tumors are only partially responsive to ICB therapies, including bintrafusp alfa (38).”
Self-citationDavid, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180
Self-citationHicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications · doi:10.1038/s41467-021-25393-x · Cited by 83
Self-citation
Cited by
Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., & Xiao, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01744-8 · Cited by 977
“Especially, double blockage of LAIR-1 and TGF-β can support totally tumor elimination by PD-L1 [495].”
BackgroundInfluentialThe Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics
Prakash, J., & Shaked, Y. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0002 · Cited by 366
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
“A recent study also demonstrated that inhibition of TGF-β and leukocyte-associated immunoglobin like receptor-1 (LAIR-1) can remodel TME, thereby enabling programmed-death ligand 1 (PD-L1)-mediated tumor eradication.(272) Dual-blockade of CD73-TGFβ promotes a multifaceted inflammatory environment in TNBC, by diminishi…”
BackgroundReviewing the Regulators of COL1A1
Devos, H., Zoidakis, J., Roubelakis, M. G., Latosinska, A., & Vlahou, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210004 · Cited by 119
Metadata
- Authors
- Horn, L. A., Chariou, P. L., Gameiro, S. R., Qin, H., Iida, M., Fousek, K., Meyer, T. J., Cam, M., Flies, D., Langermann, S., Schlom, J., & Palena, C.
- Venue
- Journal of Clinical Investigation
- Published
- 2022-04-15
- Volume
- 132
- Issue
- 8
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W4214601193
- Cited by
- 127
- References
- 18
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.